Posts tagged Thomas Shrader
Leerink starts Verona at buy

Leerink launched coverage of Verona Pharma (NADAQ:VRNA; AIM:VRP) with a “buy” rating and $22 price target after its recent cross-listing from the London Stock Exchange to NASDAQ. The stock closed at $13.52 on May 19.

Read More
Analysts starts Tocagen at buy, MP

Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5.

Read More
Stifel ups Esperion price target to $45

Stifel raised its price target for Esperion Therapeutics (NASDAQ:ESPR) to $45 from $30. The stock closed at $29.33 on March 2.

Read More
Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase 3 trial of AGS-003 in metastatic renal cell carcinoma (RCC) patients.

Read More
Stifel ups Momenta price target to $30

Stifel raised its price target for Momenta Pharmaceuticals (NASDAQ:MNTA) to $30 from $20 after a district court yesterday afternoon ruled that Teva Pharmaceutical’s Copaxone Q3W patents were invalid due to obviousness. The stock closed at $15.10 on Jan. 30.

Read More
Stifel downgrades Nivalis to hold

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with homozygous F508del CF that were stably on Orkambi. The stock closed at $6.25 on Monday.

Read More
Stifel downgrades Vitae Pharma to hold

Stifel downgraded Vitae Pharmaceuticals (NASDAQ:VTAE) to “hold” from “buy” with a new price target of $21 after the company accepted a merger agreement from Allergan (NYSE:AGN) valued at $639-million or $21 a share.

In early trading on Wednesday, Vitae is quoted at $20.94, up $12.84.

Read More
Stifel starts Selecta Biosciences at buy

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday.

“Selecta’s SVP-Rapamycin technology has the potential to open the doors of immunological tolerance and allow patients to be treated with recombinant protein ‘creations’ designed to combat disease,” writes analyst Thomas Shrader.

Read More